GEP20125413B - Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1h-1, 2, 4-triazol-1-yl)-1-[(phosphonooxy) methyl]-1h-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine - Google Patents

Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1h-1, 2, 4-triazol-1-yl)-1-[(phosphonooxy) methyl]-1h-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine

Info

Publication number
GEP20125413B
GEP20125413B GEAP200610811A GEAP2006010811A GEP20125413B GE P20125413 B GEP20125413 B GE P20125413B GE AP200610811 A GEAP200610811 A GE AP200610811A GE AP2006010811 A GEAP2006010811 A GE AP2006010811A GE P20125413 B GEP20125413 B GE P20125413B
Authority
GE
Georgia
Prior art keywords
methyl
dioxoethyl
phosphonooxy
pyrrolo
triazol
Prior art date
Application number
GEAP200610811A
Other languages
English (en)
Inventor
Chung-Pin H Chen
Dawn Digiugno
Qi Gao
Chong-Hui Gu
Jaquan Kalani Levons
Bing-Shiou Yang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of GEP20125413B publication Critical patent/GEP20125413B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GEAP200610811A 2005-12-14 2006-12-13 Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1h-1, 2, 4-triazol-1-yl)-1-[(phosphonooxy) methyl]-1h-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine GEP20125413B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75024705P 2005-12-14 2005-12-14

Publications (1)

Publication Number Publication Date
GEP20125413B true GEP20125413B (en) 2012-03-12

Family

ID=38163502

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP200610811A GEP20125413B (en) 2005-12-14 2006-12-13 Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1h-1, 2, 4-triazol-1-yl)-1-[(phosphonooxy) methyl]-1h-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine

Country Status (17)

Country Link
US (1) US7851476B2 (enExample)
EP (1) EP1963342A2 (enExample)
JP (1) JP5400387B2 (enExample)
KR (1) KR20080077010A (enExample)
CN (1) CN101365708B (enExample)
AU (1) AU2006326432B2 (enExample)
BR (1) BRPI0619851A2 (enExample)
CA (1) CA2635717A1 (enExample)
EA (1) EA014706B1 (enExample)
GE (1) GEP20125413B (enExample)
IL (1) IL191769A (enExample)
MY (1) MY144293A (enExample)
NO (1) NO20082477L (enExample)
NZ (2) NZ592684A (enExample)
UA (1) UA94928C2 (enExample)
WO (1) WO2007070589A2 (enExample)
ZA (1) ZA200805063B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7745625B2 (en) * 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
CN102076686B (zh) * 2008-06-25 2013-03-06 百时美施贵宝公司 作为hiv附着抑制剂的二酮哌啶衍生物
WO2009158394A1 (en) * 2008-06-25 2009-12-30 Bristol-Myers Squibb Company Diketo azolopiperidines and azolopiperazines as anti-hiv agents
ES2383149T3 (es) * 2008-09-04 2012-06-18 Bristol-Myers Squibb Company Composicion farmacéutica estable para la administración optimizada de un inhibidor de la unión del VIH
ES2585396T3 (es) 2010-12-02 2016-10-05 VIIV Healthcare UK (No.5) Limited Alquilamidas como inhibidores de la unión del VIH
ES2539908T3 (es) * 2011-01-31 2015-07-07 Bristol-Myers Squibb Company Métodos de preparación de un compuesto profármaco inhibidor de la fijación del VIH e intermedios
EP2696937B1 (en) 2011-04-12 2017-05-17 VIIV Healthcare UK (No.5) Limited Thioamide, amidoxime and amidrazone derivatives as hiv attachment inhibitors
ES2616268T3 (es) 2011-08-29 2017-06-12 VIIV Healthcare UK (No.5) Limited Derivados condensados de diamina bicíclica como inhibidores de la unión de VIH
ES2609579T3 (es) 2011-08-29 2017-04-21 VIIV Healthcare UK (No.5) Limited Derivados espiro de diamina bicíclica como inhibidores de la unión del VIH
US9193725B2 (en) 2012-03-14 2015-11-24 Bristol-Meyers Squibb Company Cyclic hydrazine derivatives as HIV attachment inhibitors
ES2616492T3 (es) 2012-08-09 2017-06-13 VIIV Healthcare UK (No.5) Limited Derivados de piperidina amida como inhibidores de la fijación del VIH
ES2616432T3 (es) 2012-08-09 2017-06-13 VIIV Healthcare UK (No.5) Limited Derivados de alquenos tricíclicos como inhibidores de la unión del VIH
TW201946625A (zh) 2013-11-15 2019-12-16 美商阿克比治療有限公司 {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式,其組合物及用途
RU2663466C1 (ru) * 2017-03-20 2018-08-06 Общество с ограниченной ответственностью "МБА-групп" Композиция для профилактики и/или лечения вич-инфекции
CN110913861B (zh) 2017-06-29 2024-01-09 G1治疗公司 G1t38的形态学形式及其制造方法
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
AU2020262100B2 (en) 2019-04-24 2023-03-16 Elanco Us Inc. A 7H-pyrrolo[2,3-d]pyrimidine JAK-inhibitor
SG11202111907UA (en) 2019-04-30 2021-11-29 Beijing Tide Pharmaceutical Co Ltd Solid form of diaminopyrimidine compound or hydrate thereof, preparation method therefor, and application thereof
KR102886764B1 (ko) 2019-06-06 2025-11-14 젠플리트 테라퓨틱스 (상하이) 아이엔씨. Cdk9 억제제의 결정다형 및 이의 제조방법과 용도
EP3996707A4 (en) 2019-07-08 2023-02-22 Rezolute, Inc. CRYSTALLINE FORMS OF PLASMACALLICREIN INHIBITORS
PL4011881T3 (pl) 2019-08-06 2025-04-07 Wuxi Biocity Biopharmaceutics Co., Ltd. Postacie krystaliczne inhibitora atr i ich zastosowanie

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB944443A (enExample) * 1959-09-25 1900-01-01
GB8615562D0 (en) * 1986-06-25 1986-07-30 Maggioni Farma Aminoalcohols
WO1990007926A1 (en) 1989-01-20 1990-07-26 Pfizer Inc. 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines
US5023265A (en) * 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
IL99843A0 (en) 1990-11-01 1992-08-18 Merck & Co Inc Synergistic combination of hiv reverse transcriptase inhibitors
US5811432A (en) * 1990-11-09 1998-09-22 Pfizer Inc Azaoxindole derivatives
US5192770A (en) * 1990-12-07 1993-03-09 Syntex (U.S.A.) Inc. Serotonergic alpha-oxoacetamides
DK0594702T3 (da) 1991-07-03 1997-07-21 Upjohn Co Substituerede indoler som midler mod AIDS
US5124327A (en) * 1991-09-06 1992-06-23 Merck & Co., Inc. HIV reverse transcriptase
WO1993005020A1 (en) 1991-09-06 1993-03-18 Merck & Co., Inc. Indoles as inhibitors of hiv reverse transcriptase
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
IT1265057B1 (it) 1993-08-05 1996-10-28 Dompe Spa Tropil 7-azaindolil-3-carbossiamidi
US5424329A (en) * 1993-08-18 1995-06-13 Warner-Lambert Company Indole-2-carboxamides as inhibitors of cell adhesion
GB9420521D0 (en) 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
GB9600559D0 (en) 1996-01-11 1996-03-13 British Biotech Pharm Use of chemokines
CA2264231A1 (en) * 1996-08-29 1998-03-05 Takeda Chemical Industries, Ltd. Cyclic ether compounds as sodium channel modulators
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
WO1998028292A1 (en) 1996-12-23 1998-07-02 Smithkline Beecham Corporation Novel piperidine containing compounds
AU1454599A (en) 1997-11-10 1999-05-31 Dana-Farber Cancer Institute Compounds inhibiting cd4-gp120 interaction and uses thereof
RU2217421C2 (ru) 1998-03-26 2003-11-27 Шионоги & Ко., Лтд. Производные индола, обладающие антивирусной активностью
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
EP1091738B1 (en) 1998-06-30 2006-12-06 Eli Lilly And Company BICYCLIC sPLA 2 INHIBITORS
EP1107758A2 (en) 1998-08-28 2001-06-20 Scios Inc. Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
GB9905010D0 (en) 1999-03-04 1999-04-28 Merck Sharp & Dohme Therapeutic agents
CZ20014126A3 (cs) 1999-05-21 2002-03-13 Scios Inc. Indolové deriváty jako inhibitory p38 kinasy
US6469006B1 (en) 1999-06-15 2002-10-22 Bristol-Myers Squibb Company Antiviral indoleoxoacetyl piperazine derivatives
TWI269654B (en) 1999-09-28 2007-01-01 Baxter Healthcare Sa N-substituted indole-3-glyoxylamide compounds having anti-tumor action
US6476034B2 (en) * 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US20020061892A1 (en) 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
DE60113543T2 (de) 2000-07-10 2006-07-13 Bristol-Myers Squibb Co. Zusammensetzung und antivirale wirkung von substituierten indol-oxo-aceto-piperidin-derivaten
US6573262B2 (en) * 2000-07-10 2003-06-03 Bristol-Myers Sqibb Company Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives
DE10037310A1 (de) 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
KR20030079979A (ko) 2001-02-02 2003-10-10 브리스톨-마이어스스퀴브컴파니 치환된 아자인돌옥소아세틱 피페라진 유도체의 조성물 및항바이러스 활성
US20030207910A1 (en) * 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US6825201B2 (en) 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
BR0214020A (pt) 2001-11-09 2004-10-13 Scios Inc Método para tratar fibrose cìstica
US20030236277A1 (en) 2002-02-14 2003-12-25 Kadow John F. Indole, azaindole and related heterocyclic pyrrolidine derivatives
WO2003082881A2 (en) 2002-03-28 2003-10-09 Procyon Biopharma Inc. Pyridoxal-5-phosphate derivatives as hiv integrase inhibitors
US7037913B2 (en) 2002-05-01 2006-05-02 Bristol-Myers Squibb Company Bicyclo 4.4.0 antiviral derivatives
US20040063744A1 (en) * 2002-05-28 2004-04-01 Tao Wang Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
US7348337B2 (en) * 2002-05-28 2008-03-25 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
US20040106104A1 (en) 2002-06-11 2004-06-03 Pin-Fang Lin Viral envelope mediated fusion assay
US6900206B2 (en) * 2002-06-20 2005-05-31 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives
US20040063746A1 (en) * 2002-07-25 2004-04-01 Alicia Regueiro-Ren Indole, azaindole and related heterocyclic ureido and thioureido piperazine derivatives
US20050075364A1 (en) * 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
OA13235A (en) 2003-08-14 2006-12-13 Pfizer Piperazine derivatives for the treatment of HIV infections.
US20050124623A1 (en) * 2003-11-26 2005-06-09 Bender John A. Diazaindole-dicarbonyl-piperazinyl antiviral agents
US7745625B2 (en) * 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20050215544A1 (en) * 2004-03-24 2005-09-29 Pin-Fang Lin Methods of treating HIV infection
US7776863B2 (en) * 2004-03-24 2010-08-17 Bristol-Myers Squibb Company Methods of treating HIV infection
US20050215543A1 (en) * 2004-03-24 2005-09-29 Pin-Fang Lin Methods of treating HIV infection
US7449476B2 (en) * 2004-05-26 2008-11-11 Bristol-Myers Squibb Company Tetrahydrocarboline antiviral agents
US7087610B2 (en) * 2004-06-03 2006-08-08 Bristol-Myers Squibb Company Benzothiazole antiviral agents
WO2005121094A1 (en) 2004-06-09 2005-12-22 Pfizer Limited Piperazine and piperidine derivatives as anti-hiv-agents
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US7183284B2 (en) * 2004-12-29 2007-02-27 Bristol-Myers Squibb Company Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents
US7396830B2 (en) * 2005-10-04 2008-07-08 Bristol-Myers Squibb Company Piperazine amidines as antiviral agents
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US7501419B2 (en) * 2006-04-25 2009-03-10 Bristol-Myers Squibb Company 4-Squarylpiperazine derivatives as antiviral agents

Also Published As

Publication number Publication date
US7851476B2 (en) 2010-12-14
NZ592684A (en) 2012-07-27
AU2006326432B2 (en) 2012-07-12
ZA200805063B (en) 2009-10-28
NO20082477L (no) 2008-09-05
US20070155702A1 (en) 2007-07-05
IL191769A0 (en) 2008-12-29
UA94928C2 (en) 2011-06-25
WO2007070589A3 (en) 2007-09-27
NZ568776A (en) 2011-06-30
CN101365708A (zh) 2009-02-11
EA200801529A1 (ru) 2009-02-27
CA2635717A1 (en) 2007-06-21
CN101365708B (zh) 2012-12-12
KR20080077010A (ko) 2008-08-20
AU2006326432A1 (en) 2007-06-21
WO2007070589A2 (en) 2007-06-21
EA014706B1 (ru) 2011-02-28
MY144293A (en) 2011-08-29
EP1963342A2 (en) 2008-09-03
JP2009521414A (ja) 2009-06-04
JP5400387B2 (ja) 2014-01-29
BRPI0619851A2 (pt) 2011-10-25
IL191769A (en) 2011-08-31

Similar Documents

Publication Publication Date Title
GEP20125413B (en) Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1h-1, 2, 4-triazol-1-yl)-1-[(phosphonooxy) methyl]-1h-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine
AU2003213162A8 (en) Magnet control system for battery powered living tissue stimulators
WO2005113747A3 (de) Multizelluläre gewebe- und organkultursysteme
EP1850696A4 (en) MODULAR MULTIPLE PATIENT SUPPORT SYSTEM
DE50313629D1 (de) Chirurgisches instrument zum fräsen der hüftpfanne
EP2005569A4 (en) Energy generating systems for implanted medical devices
EP1945292A4 (en) DIAPHRAGM ENTRANCE FOR POSTERIORS SURGICAL ACCESS
IL184310A0 (en) Process for preparing 2-methyl-1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine
EP2262459A4 (en) SYNCHRONIZED DIAGNOSTIC MEASUREMENT FOR COOKLEAR IMPLANTS
IL190541A0 (en) Methods for manufacturing dental implant components
IL178141A (en) Use of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1h-pyrrolo[2,3-c]pyridine-3-yl]-1,2-dioxoethyl]-piperazine in the manufacture of a medicament for use in conjunction with at least one other agent used for treatment of aids or hiv infection
EP2028503B8 (en) Method and device for determining state of health of the battery, and battery power supply system
GB0603426D0 (en) Image acquisition system for generation of three-dimensional models
EP2142543B8 (en) Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
GB2464652B (en) Improved methods for the generation of hepatocyte-like cells from human blastocyst-derived stem (hBS)
GB2431165B (en) Medium for growing human embryonic stem cells
EP1841500A4 (en) SOLDER PLATE CONTACT FOR IMPLANT MEDICAL DEVICES
PT2020410E (pt) Derivados de pirido[2,3-d]pirimidina, sua preparação, sua aplicação em terapêutica
ZA200803487B (en) Process for the preparation of an electrolyte
IL184825A0 (en) Aqueous gel formulations containing 1-(2-methylpropyl)-1h-imidazo [4,5-c][1,5] napthyridin-4-amine
NL301118I1 (enExample)
HK1117537A (en) Crystalline forms of 1-benzoyl-4-[2-]4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1h-pyrrolo[2,3-c]pyridin-3-yl[-1,2-dioxoethyl]-piperazine
PL378524A1 (pl) Układ do zasilania systemu pomiarowego diagnostyki medycznej
SG118298A1 (en) Method for monitoring ion implant doses
WO2005062691A8 (en) Biogeometry shapes & methodology for biological energy balancing